The Company

Novo Nordisk A/S is a global leader in pharmaceuticals and healthcare, primarily specializing in diabetes and obesity treatments. Based in Denmark, it develops and markets a comprehensive portfolio of products, including injectable and oral therapies, hormone treatments, and biosolutions.

Financials

In fiscal year 2024, Novo Nordisk reported revenue of DKK 290.4 billion (≈ USD 42.1 billion) and net income of DKK 100.9 billion (≈ USD 14.5 billion). Year-over-year revenue growth was approximately 25%, driven primarily by blockbuster drugs like Ozempic and Wegovy.

TAM / CAGR

• Global diabetes drug market: USD 79.4 billion in 2023, projected to reach USD 145 billion by 2032, growing at ~6.9% CAGR.
• GLP‑1 analogues market (e.g., semaglutide): valued at USD 47.4 billion in 2024 and expected to hit USD 471 billion by 2032 at ~33.2% CAGR.
• Diabetes devices market: USD 30.3 billion in 2023, projected to reach USD 50.3 billion by 2030, with a CAGR of ~7.5%.